Abstract
Many studies have reported that bleomycin, anti-cancer drug, induces pulmonary fibrosis as a side effect. However, few investigations have focused on the dose-response effects of bleomycin on pulmonary fibrosis. Therefore, in the present study, we investigated the effects of different doses of bleomycin in male mice. ICR mice were given 3 consecutive doses of bleomycin: 1, 2, or 4 mg/kg in bleomycin-treated (BT) groups and saline only in vehicle control (VC) groups. The animals were sacrificed at 7 and 24 days post-instillation. The severity of pulmonary fibrosis was evaluated according to inflammatory cell count and lactate dehydrogenase (LDH) activity in the broncho alveolar lavage fluid (BALF), and lung tissues were histologically evaluated after hematoxylin and eosin (H&E), and Masson’s trichrome staining. BT groups exhibited changed cellular profiles in BAL fluid compared to the VC group, which had an increased number of total cells, neutrophils, and lymphocytes and a modest increase in the number of macrophages at 7 days post-bleomycin instillation. Moreover, BT groups showed a dose-dependent increase in LDH levels and inflammatory cell counts. However, at 24 days after treatment, collagen deposition, interstitial thickening, and granulomatous lesions were observed in the alveolar spaces in addition to a decrease in inflammatory cells. These results indicate that pulmonary fibrosis induced by 4 mg/kg bleomycin was more severe than that induced by 1 or 2 mg/kg. These data will be utilized in experimental animal models and as basic data to evaluate therapeutic candidates through non-invasive monitoring using the pulmonary fibrosis mouse model established in this study.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Antje, M., Juan Carlos, R.L., Lingqiao, W., Jack, G. and Martin, K. (2006). Models of pulmonary fibrosis. J. Ddmod., 3, 243–249.
Bethany, B.M. and Cory, M.H. (2008). Murine models of pulmonary fibrosis. Am J Physiol. Lung Cell Mol Physiol., 294, 152–160.
Bonniaud, P., Kolb, M., Gait, T., Robertson, J., Robbins, C., Stampfli, M., Lavery, C., Margetts, P.J., Roberts, A.B. and Gauldie, J. (2004). Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J. Immunol, 173, 2099–2108.
Briggs, A.D., Chandler, D.B., Jackson, RM. and Fulmer, J.D. (1985). The effect of endotoxin on bleomycin-induced lung fibrosis in the rat. Toxicol Lett., 27, 91–96.
Brown, R.F., Drawbaugh, R.B. and Marrs, T.C. (1988). An investigation of possible models for the production of progressive pulmonary fibrosis in the rat. The effects of repeated intratracheal instillation of bleomycin. Toxicol., 51, 101–110.
Hemmati, A.A., Nazari, Z., Motlagh, M.E. and Goldasteh, S. (2002). The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat. Pharmacol. Res., 46, 229–234.
Higashiyama, H., Yoshimoto, D., Kaise, T., Matsubara, S., Fujiwara, M., Kikkawa, H., Asano, S. and Kinoshita, M. (2007). Inhibition of activin receptor-like kinase 5 attenuates Bleomycin-induced pulmonary fibrosis. Exp Mol Pathol., 83, 39–46.
Jack, G., Martin, K., Kjetil, A., Gail, M., Philippe, B. and David, W. (2006). Smad3 signaling involved in pulmonary fibrosis and emphysema. ProcAm Thorac. Soc, 3, 696–702.
John, S.L., et al. (1990). BLEOMYCIN: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmac. Ther., 47, 347–358.
Manoury, B., Nenan, S., Guenon, I., Lagente, V. and Boichot, E. (2007) Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Int Immunophar-macol, 7, 900–911.
Moeller, A., Ask, K., Warburton, D., Gauldie, J. and Kolb, M. (2008). The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J. Biochem Cell Biol., 40, 362–382.
Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M. and Arimura, A. (2008). Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J. Pharmacol., 590, 400–408.
Ou, X.-M., Li, W.-C., Liu, D.-S., Li, Y.-R., Wen, F.-Q., Feng, Y.-L., Zhang, S.-E., Huang, X.-Y., Wang, T., Wang, K., Wang, X. and Chen, L. (2009). VEGFR-2 antagonist SU5416 attenuates bleomycin- induced pulmonary fibrosis in mice. Int. Immunophar-macol, 9, 70–79.
Ouchi, H., Fujita, M., Ikegame, S., Ye, Q., Inoshima, I., Harada, E., Kuwano, K. and Nakanishi, Y. (2008). The role of collage-nases in experimental pulmonary fibrosis. Pulm Pharmacol. Ther., 21, 401–408.
Saito, E., Tasaka, S., Inoue, K., Miyamoto, K., Nakano, Y., Ogawa, Y., Yamada, W., Shiraishi, Y., Hasegawa, N., Fujishima, S., Takano, H. and Ishizaka, A. (2008). Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am. J. Respir. Cell. Mol. Biol, 38, 566–571.
Steven, E.M., Robin, J.M., Geoffrey, J.L. and Darryl, A.K. (2004). Evaluation of experimental models of idiopathic pulmonary fibrosis. J. Ddmod., 1, 329–336.
Thomas, A.W. (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest., 117, 524–529.
Thomas, W.H., Joan, E.G., Karen, M.R., Andrew, C.J., Carroll, E.C. and Jerold, A.L. (1981). Bleomycin-induced pulmonary fibrosis: correlation of biochemical, physiological, and histological changes. Toxicol. Appl. Pharmacol., 60, 360–367.
Tom, W.-M. and Montgomery, M.R. (1980). Biochemical and morphological assessments of bleomycin pulmonary toxicity in rats. Toxicol. Appl. Pharmacol., 53, 64–74.
Zhou, X.-M., Zhang, G.-C., J.-X. and Hou, J. (2007). Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. J. Ethnopharmacol., 111, 255–264.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kim, S.N., Lee, J., Yang, HS. et al. Dose-response Effects of Bleomycin on Inflammation and Pulmonary Fibrosis in Mice. Toxicol Res. 26, 217–222 (2010). https://doi.org/10.5487/TR.2010.26.3.217
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2010.26.3.217